C21orf91-OT1: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: C21orf91-OT1

NCBI ID: G246312

C21orf91-OT1

Other Name(s): C21orf91-OT1 variant 1 | C21orf91 overlapping transcript 1 | C21orf91 overlapping transcript 1, transcript variant 1 | D21S2089E | NCRNA00285

C21orf91-OT1: A Potential Drug Target and Biomarker for Ovarian Cancer

Introduction

Ovarian cancer is a leading cause of cancer-related deaths in women, with a high incidence and poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for advanced ovarian cancer remains stagnant. Therefore, there is a need for new diagnostic and therapeutic approaches to improve outcomes for patients.

C21orf91-OT1 is a gene that has been identified as a potential drug target and biomarker for ovarian cancer. In this article, we will explore the biology of C21orf91-OT1 and its potential implications for the treatment of ovarian cancer.

C21orf91-OT1: A Potential Drug Target

C21orf91-OT1 is a 91kDa transmembrane protein that is expressed in various tissues, including ovaries, lungs, and brain. It is a member of the evolutionarily conserved superfamily of cytoskeletal proteins, known as the A-type cytoskeleton-associated protein (ACP) family.

ACP proteins are involved in various cellular processes, including cytoskeletal organization, cell adhesion, and signaling. Therefore, C21orf91-OT1 is likely involved in these processes in the development and progression of ovarian cancer.

C21orf91-OT1 has been shown to be involved in the regulation of cell adhesion and cytoskeletal organization. For example, studies have shown that overexpression of C21orf91-OT1 can enhance the aggressive ability of ovarian cancer cells, leading to their enhanced ability to spread and form tumors.

Furthermore, C21orf91-OT1 has been shown to play a role in the regulation of mitosis. In ovarian cancer cells, C21orf91-OT1 has been shown to promote the G1/G2 phase of cell division and the maintenance of a stable microtubule organization, which are critical for the proper execution of mitosis.

C21orf91-OT1: A Potential Biomarker

C21orf91-OT1 may also be a potential biomarker for ovarian cancer. The identification of biomarkers for ovarian cancer has the potential to improve diagnostic accuracy and guide the choice of treatment options.

Studies have shown that C21orf91-OT1 is overexpressed in various types of ovarian cancer, including epithelial, stromal, and epithelial cancer. Therefore, it may be a useful biomarker for the diagnosis and evaluation of ovarian cancer.

Moreover, C21orf91-OT1 has been shown to be involved in the regulation of cell cycle progression. Overexpression of C21orf91-OT1 has been shown to promote the G1/G2 phase of cell division and the maintenance of a stable microtubule organization, which are critical for the proper execution of the cell cycle.

Conclusion

In conclusion, C21orf91-OT1 is a gene that has the potential to be a drug target and biomarker for ovarian cancer. Its involvement in cell adhesion, cytoskeletal organization, and cell cycle regulation suggests that it may play a critical role in the development and progression of ovarian cancer. Further studies are needed to confirm its potential and to explore its clinical applications in the treatment of ovarian cancer.

Protein Name: C21orf91 Overlapping Transcript 1

The "C21orf91-OT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C21orf91-OT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets